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Despite the indisputable mortality advantages of implantable cardioverter defibrillators 
(ICDs), no consensus exists regarding their impact on quality of life (QoL). This system-
atic review investigates differences in QoL between patients with ICDs and controls. 
We systematically searched the MEDLINE, EMBASE, Cochrane, Web of Science, and 
PsychINFO databases. Articles were included if they were published after the year 2000 
and reported on original studies with a control group. Five randomized controlled trials 
with a total of 5,138 patients and 10 observational studies with a total of 1,513 patients 
met the inclusion criteria. Nine studies found comparable QoL for ICD recipients and 
patients in the control groups, three studies found an increased QoL for ICD patients, 
and three studies found a decreased QoL for ICD patients. The question of whether QoL 
relates to ICD therapy cannot be answered conclusively due to the heterogeneity of the 
existing studies. Lower QoL was apparent among patients with an ICD who experienced 
several device discharges. Medical staff should be particularly aware of the signs of both 
psychological and physical disorders in these patients. Further investigations on QoL in 
ICD patients are desirable, but ethical reasons restrict the conduct of randomized trials.
Keywords: implantable defibrillator, quality of life, life style, anxiety, depression
iNTRODUCTiON
Since the first implantation of an implantable cardioverter defibrillator (ICD) in a human being in 
1980 (1), multiple clinical trials have assessed its impact on mortality and observed beneficial effects 
among ICD patients (2–9). Consequently, ICD therapy has become a widespread treatment option 
for patients who are at risk of sudden cardiac death (10, 11). In addition to its impact on survival, the 
influence of ICD implantation on patients’ health-related quality of life (QoL) has become increas-
ingly important. Improved QoL in cardiac patients after ICD placement might be explained by the 
reassurance and protection afforded to these patients by their device. Additionally, the ICD may 
reduce patients’ health concerns and enable them to return to an autonomous and vital lifestyle (12, 
13). However, living with an implanted device anticipating or recalling unpredictable and painful 
shocks may result in feelings of dependence, psychological distress, or fear. Possible consequences 
include anxiety, depression, or avoidance behaviors, such as self-imposed limitations on physical 
activities, employment, or driving (14–16). These reactions and aesthetic aspects may result in a 
reduced QoL among patients with an ICD.
TABLe 2 | The databases and the field search settings used.
Database Field search
MEDLINE (accessed by PubMed) Title/abstract, MeSH terms
Cochrane Title, abstract, keywords
Expander: word variations have 
been searched
EMBASE (Embase Classic + Embase) 
(accessed by OvidSP)
Title, abstract, subject heading
Web of Science Title, abstract, author keyword, 
keywords plus®
PsychINFO (accessed by Ebsco Host) All fields
Expander: apply related words
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Because the implantation of an ICD is often a prophylactic 
therapy, not all individual patients who receive such a device will 
experience lifesaving shocks and derive a survival benefit from it. 
This fact and the divergent arguments supporting either a reduced 
or an increased QoL among patients with an ICD warrant an explo-
ration of patients’ actual perceptions of their QoL following ICD 
implantation. A variety of cardiac patients exist who are alternately 
treated with an ICD and could potentially serve as a control group. 
We represent this variety in our systematic review to provide an 
extensive overview. The primary objective of our systematic review 
was to investigate whether the health-related QoL of patients with 
ICDs differs from that of patients who have received medical treat-
ment and from that of patients who have undergone pacemaker 
implantation or received no intervention. If they were reported 
in the studies, we also considered ICD shocks or patients’ age as 
secondary objectives because they are linked to QoL.
MeTHODS
Definition of Search Strategy
The methods used in our systematic review are based on the 
Cochrane Handbook for Systematic Reviews of Interventions 
(17). Table 1 includes a complete list of search terms. We searched 
the MEDLINE (accessed via PubMed), EMBASE (accessed via 
Ovid), Cochrane, Web of Science, and PsychINFO (accessed 
by Ebsco Host) databases, including both broad bibliographic 
databases and subject-specific databases. Details on the searched 
fields within the databases are included in Table  2. The initial 
search was not limited by any constraints concerning the article 
type, the language, the date of publication, or the electronic avail-
ability of the abstracts.
Study Selection
From the initial search results, we included studies in the review 
if they evaluated the influence of an ICD on QoL, were original 
studies, and were published in either German or English after 
the year 2000. Since 2000, all ICD devices have incorporated 
high-grade technology that is intended to reliably discriminate 
between supraventricular and ventricular rhythms (1). To be 
included, patients’ QoL or a closely related endpoint had to be the 
primary outcome of the study in question. Studies were incorpo-
rated irrespective of how QoL was measured and whether they 
assessed primary or secondary device implantation.
TABLe 1 | Search terms in the databases.
(implantable OR internal)
AND
(cardioverter OR defibrillator OR ICD)
AND
(quality of life OR QOL OR adaptation OR acceptance OR attitude to health 
OR health status OR health state OR psychological OR psychologic OR 
emotional OR mental OR mood disorder OR mental disorder OR psychiatric 
disorder OR anxiety OR depression OR depressive OR panic OR fear OR 
worry OR anger OR frustration OR sadness OR self-doubt OR distress 
OR stress OR lability OR uncertainty OR concern OR helplessness OR 
dependence OR hypervigilance OR welfare OR well-being OR wellbeing OR 
protective OR comfort OR relief OR safety OR independence OR physical 
OR mobility OR pain OR vitality)
Case studies, cost-effectiveness analyses, systematic reviews, 
comments, letters, and overview texts were excluded, as were 
studies without a clearly defined control group without ICD. To 
provide a broad overview, we did not further specify the type 
of comparison, though the comparison between single studies 
became more difficult as a consequence. Possible therapeutic alter-
natives included no intervention, pacemaker implantation, and 
medical treatment. We also did not include studies in the review 
that considered the effects of shocks or device recalls on QoL as 
their primary objective or studies on resynchronization therapy.
Selection Procedure
Searches were conducted in all databases on January 13, 2014. 
Identified records were exported to EndNote X7 and filtered 
automatically for duplicates. The selection of relevant articles was 
supervised by a clinical cardiologist. The first level of selection 
included an independent screening of titles by two reviewers, a 
health economist and a mathematician. The reviewers’ relative 
distance from cardiology supported the neutral selection of 
articles via the application of the defined inclusion and exclusion 
criteria. The titles of the identified articles were jointly screened, 
and a decision regarding each article’s inclusion was reached fol-
lowing discussion and the achievement of consensus. The second 
step of screening entailed the consideration of the abstracts of the 
remaining articles in a manner similar to that of the first level of 
selection. The third step entailed full-text screening. The references 
of the resulting studies, as well as those of each of the systematic 
reviews identified via the abstract screening, were subsequently 
hand-searched by one reviewer for further relevant studies.
Quality Assessment and the  
Grouping of Studies Using Different 
Subcategories of QoL
One reviewer assessed the level of evidence of the studies that were 
included using the Oxford Centre for Evidence-Based Medicine 
Levels of Evidence (18). Additionally, the study quality was 
evaluated by the consideration of the risk for bias and confounding 
and for the existence of a comprehensive and complete report of 
methodological details and results (++/+/− = high/good/poor 
methodological quality).
For the aggregation of studies, one reviewer defined different 
subcategories of QoL (e.g., physical and mental health) based on 
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each of the applied questionnaires and their subscales. For each 
study, a thorough inspection of the questions contained in the 
respective questionnaires was conducted to determine which of 
the defined subcategories would be examined by a particular study.
ReSULTS
The selection process for the studies included in this review is 
illustrated in Figure 1. The database search yielded 9,904 records, 
of which we finally included 15 studies as follows: 5 randomized 
controlled trials (RCTs) (19–23), 3 observational studies (24–26), 
and 7 cross-sectional studies (27–33). An overview of study 
characteristics, findings, and quality assessment is included in 
Table 3.
The studies included in our review varied with respect to the 
control groups and inclusion and exclusion criteria, as well as the 
demographic characteristics of the study. For example, one study 
investigated QoL in children (31), and another study investigated 
FiGURe 1 | Literature search flowchart.
TABLe 3 | Characteristics and primary results from the included studies.
Study, year, country,  
type of study
Type of prevention: primary/secondary,  
inclusion and exclusion criteriaa
Controlb No. of patients in 
study (iCD group, 
control group), 
enrollment (e), 
follow-up (FU)
Conclusion: iCD patients’ QoL  
compared to control group
LOe/
study 
qualityc
worse Neutral Better
Mark et al. (20)
2008
USA, Canada,  
New Zealand
Multicenter RCT 
(SCD-HeFT)
Prevention: prim.
Inclusion: NYHA class II or III, chronic, stable congestive heart failure 
due to either ischemic or non-ischemic causes, LVEF ≤ 35%
Exclusion: n.r.
Med. 
(830 patients: 
conventional medical 
therapy plus amiodarone, 
and 833 patients: 
conventional medical 
therapy plus amiodarone 
placebo)
2479 
(816, 1663)
E: 1997–2001
FU: 30 months
✓
2b++
“In a large primary prevention population 
with moderately symptomatic heart failure, 
single lead ICD therapy was not associated 
with any detectable adverse quality-of-life 
effects over 30 months of follow-up”
Noyes et al. (21)
2007
USA
Multicenter RCT 
(MADIT II)
Prevention: prim.
Inclusion: prior MI, LVEF ≤ 30%
Exclusion: Europeans, missing baseline QoL data, patients from study 
centers with poor data quality
Med. 
(conventional medical 
treatment)
1089 
(658, 431)
E: 1997–2001
FU: maximum 
48 months
✓
2b++
“strong evidence […] [that] the ICD provides 
little or no quality of life benefits”
Passman et al. (22)
2007
USA
Multicenter RCT 
(DEFINITE)
Prevention: prim.
Inclusion: LVEF ≤ 35% (not caused by CAD), history of symptomatic 
heart failure, either non-sustained VT or ≥10 premature ventricular 
depolarizations per hour at baseline
Exclusion: n.r.
Med. 
(conventional medical 
therapy)
453 
(227, 226)
E: 1998–2002
FU: maximum 
63 months
✓
2b++
“HRQL (health-related QoL) was not 
affected by ICD implantation in patients 
in the defibrillators in Non-ischemic 
Cardiomyopathy Treatment Evaluation 
study”
Irvine et al. (19)
2002
Canada
Multicenter RCT 
(CIDS)
Prevention: sec.
Inclusion: documented sustained ventricular arrhythmias
Exclusion: recent or acute MI or electrode imbalance, not able to read 
English
Med. 
(amiodarone)
317 
(157, 160)
E: 1990–1997
FU: 12 months
✓
2b+
“Quality of life is better with ICD therapy than 
with amiodarone therapy”
Hsu et al. (26)
2002
USA
Cohort study
Prevention: sec.
Inclusion: discharged alive after hospitalization for a live-threatening 
ventricular arrhythmia, primary diagnosis of cardiac arrest or VT or VF
Exclusion: no evidence of cardiac arrest, sustained VT or VF in clinical 
chart, arrhythmia occurred during the first 48 h after acute MI, non-
sustained VT as the only arrhythmia, transient and reversible cause of 
arrhythmia (drug toxicity, hypoxia, electrolyte imbalance), <18 years, 
non-English speaking, severe or moderate dementia, life expectancy 
<6 months, AIDS, discharged to somewhere else but home, no 
member of Kaiser Northern California System
Med. 
(91 patients: 
amiodarone, and 79 
patients: antiarrhythmic 
medications other than 
amiodarone)
264 
(94, 179)
E: 1995–1998
FU: 24 months
✓
2b+
“QOL improves more after ICD than after 
amiodarone therapy”
(Continued)
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Study, year, country,  
type of study
Type of prevention: primary/secondary,  
inclusion and exclusion criteriaa
Controlb No. of patients in 
study (iCD group, 
control group), 
enrollment (e), 
follow-up (FU)
Conclusion: iCD patients’ QoL  
compared to control group
LOe/
study 
qualityc
worse Neutral Better
Schron et al. (23)
2002
USA
Multicenter RCT 
(AVID)
Prevention: sec.
Inclusion: VF or symptomatic VT (including sustained VT resulting in 
syncope or sustained VT in the setting of LVEF ≤ 40% and clinically 
important symptoms of hemodynamic compromise), survival of at least 
1 year
Exclusion: n.r.
Med. 
(antiarrhythmic drugs)
800 
(416, 384)
E: n.r.
FU: 12 months
✓
2b−
“ICD and AAD (antiarrhythmic drugs) therapy 
are associated with similar alterations in self-
perceived QoL over 1-year follow-up”
Leosdottir et al. (28)
2006
Iceland
Cross-sectional study
Prevention: n.r.
Inclusion: all ICD patients living in Iceland at the beginning of 2002
Exclusion: not able to complete questionnaires due to mental or 
physical disabilities (assessed by caring physician)
PM 108 
(41, 67)
E: 2002–2003
FU: n.a.
✓
4+
“ICD patients had a comparable QoL with 
pacemaker recipients and were not more 
likely to suffer from anxiety, depression, or 
general psychiatric distress”
Newall et al. (29)
2007
New Zealand
Cross-sectional study
Prevention: n.r.
Inclusion: ≥18 years, able to comprehend English
Exclusion: taking antidepressant medications for pre-existing 
depression
PM 95 
(46, 49)
E: 2005
FU: n.a.
✓
4+
“Quality-of-life scores were normal for all 
ICD patients with respect to both mental 
and physical component scores, and not 
different from the pacemaker group”
Czosek et al. (31)
2012
USA
Multicenter cross-sectional 
study
Prevention: prim. and sec.
Inclusion: children between 8 and 18 and their parents
Exclusion: n.r.
PM 173 
(40, 133)
E: 2004–2008
FU: n.a.
✓
4−
“Patient- and parent-proxy-reported QOL 
is significantly affected by the presence of 
cardiac rhythm devices and is worsened in 
those patients with CHD (congenital heart 
disease) and ICD systems as opposed to 
pacing systems”
Duru et al. (27)
2001
Switzerland
Cross-sectional study
Prevention: n.r.
Inclusion: 40–70 years, first pectoral implantation of ICD or PM
Exclusion: n.r.
PM 152 
(76, 76)
E: 1993–1999
FU: n.a.
✓
4−
“There was no difference between the 
three groups (ICD with experienced shock, 
ICD without experienced shock, PM), with 
respect to scores on any aspect of the HAD 
and SF-36”
Redhead et al. (30)
2010
UK
Cross-sectional study
Prevention: sec.
Inclusion: first ICD implanted between April 2004 and March 2007 after 
MI
Exclusion: n.r.
PM & Oth. 
(49 patients: PM, 50 
patients: angioplasty, 
and 50 patients: catheter 
ablation for drug-resistant 
atrial fibrillation)
249 
(100, 149)
E: 2010
FU: n.a.
✓
4+
“Mean scores for each assessment were 
similar for each group”
TABLe 3 | Continued
(Continued)
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Study, year, country,  
type of study
Type of prevention: primary/secondary,  
inclusion and exclusion criteriaa
Controlb No. of patients in 
study (iCD group, 
control group), 
enrollment (e), 
follow-up (FU)
Conclusion: iCD patients’ QoL  
compared to control group
LOe/
study 
qualityc
worse Neutral Better
Kamphuis et al. (25)
2002
The Netherlands
Observational study
Prevention: n.r.
Inclusion: survived an out-of-hospital cardiac arrest due to VT, 
≥16 years, able to comprehend Dutch
Exclusion: n.r.
Oth. 
(antiarrhythmic drugs, 
angioplasty, or surgical 
revascularization)
168 
(133, 35)
E: n.r.
FU: 12 months
✓ 2b−
“In general, OT (other treatment) patients 
achieved a better quality of life than ICD 
patients”
Probst et al. (32)
2011
France
Cross-sectional study
Prevention: n.r.
Inclusion: Brugada Syndrome (Type 1 ECG before or after a sodium 
channel blocker challenge)
Exclusion: <18 years, no valid mailing address
Oth. 
(asymptomatic patients 
without an ICD)
190 
(138, 52)
E: n.r.
FU: n.a.
✓
4−
“BrS (Brugada Syndrome) patients have 
a good quality of life with no difference 
between implanted and non-implanted 
patients”
Opic et al. (33)
2012
The Netherlands, Belgium
Multicenter cross-sectional 
study
Prevention: n.r.
Inclusion: young adults with ToF
Exclusion: n.r.
Oth. 
(ToF patients without an 
ICD)
54 
(26, 28)
E: n.r.
FU: n.a.
✓
4−
“ToF patients with an ICD show less 
favorable psychosocial functioning 
compared to ToF patients without ICD”
Cross et al. (24)
2010
USA
Observational study
Prevention: n.r.
Inclusion: ICD therapy and/or diagnosis of CAD
Exclusion: obstructive sleep apnea, restless legs syndrome
Oth. 
(patients with CAD)
60 
(30, 30)
E: n.r.
FU: 14 days
✓
4−
“The purpose of this study was to compare 
sleep patterns between CAD and ICD 
patients […]. The primary and surprising 
finding was that CAD patients had poorer 
sleep compared with ICD patients in terms 
of sleep efficiency and total sleep time”
an.r., not reported; n.a., not applicable; NYHA, New York Heart Association Functional Classification; LVEF, left ventricular ejection fraction; MI, myocardial infarction; CAD, coronary artery disease; VT, ventricular tachycardia; VF, 
ventricular fibrillation; ToF, Tetralogy of Fallot.
bMed., medical treatment; PM, pacemaker implantation; Oth., others or treatment not specified.
cLOE, level of evidence; 2b, low-level RCT (e.g., no confidence intervals) or individual cohort study; 4, case-series and cross-sectional studies; ++/+/−, high/good/poor methodological quality.
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QoL in patients with Tetralogy of Fallot (ToF), with a mean age 
of 44 years (33). The mean age of the patients who received an 
ICD in the other studies ranged between 50 and 69 years of age.
The quality assessment revealed frequent methodological 
limitations, such as an insufficient description of the statistical 
analyses, the recruitment process, and the existence of missing 
data and their handling. Furthermore, the problem of multiple 
testing and confounding variables was often not incorporated 
into the statistical analyses.
QoL of iCD Patients Compared with  
that of Distinct Control Groups
All five of the identified RCTs (19–23) and one cohort study 
(26) compared patients who underwent ICD implantation with 
patients who received medical treatment. Medical treatment 
ranged from conventional medical therapy to treatment with 
amiodarone. Each of the RCTs assessed all-cause mortality as the 
primary endpoint and QoL as a secondary endpoint. The number 
of study participants and the quality of study was intermediate to 
high. Two RCTs reported improved QoL for patients with an ICD 
compared to patients with medical treatment. The remaining four 
studies noted no QoL differences among the groups.
Pacemaker patients served as control subjects in five cross-
sectional studies (27–31). Due to various methodological 
limitations, these studies were assessed to be of moderate to low 
quality. All studies except the one by Czosek et al. (31) yielded 
no differences regarding QoL between pacemaker patients and 
patients with an ICD. Czosek et al. considered pediatric patients 
and revealed a lower QoL for children with an ICD than for 
children implanted with a pacemaker.
Redhead et  al. (30) compared ICD patients with three 
groups of patients undergoing other typical cardiac procedures: 
pacemaker patients, patients who underwent angioplasty, and 
patients treated via catheter ablation for drug-resistant atrial 
fibrillation. The remaining four studies (24, 25, 32, 33) selected 
control subjects from patients receiving antiarrhythmic drugs, 
patients who underwent angioplasty or patients who underwent 
surgical revascularization, or had control groups that received an 
unspecified intervention. Two of these studies found decreased 
QoL for ICD patients, whereas the other two revealed comparable 
QoL in ICD and control groups. However, these studies had 
major methodological limitations. The heterogeneous results 
must therefore be considered with caution.
Different Subcategories of  
the iCD Patients’ QoL
The studies included in our review were arranged according to 
characteristics that contribute to QoL. These include physical 
and mental health, e.g., physical limitations, bodily pain, social 
functioning, anxiety, and depression.
Table  4 shows different subcategories of QoL and the stud-
ies that examined these dimensions. Studies were categorized 
depending on whether improvement or impairment was 
observed for ICD patients or whether no significant difference 
was observed. The majority of studies did not show a difference 
in QoL between ICD patients and controls.
Relationship Between QoL and  
Age in iCD Patients
The cross-sectional study by Czosek et  al. (31) and the RCT by 
Passman et al. (22) found no correlation between QoL and patients’ 
ages. Opic et al. (33) reported worse psychosocial functioning in 
younger patients. Poor QoL was noted among elderly patients by 
Hsu et al. (26). Kamphuis et al. (25) reported improved vitality but 
poorer health perception among elderly ICD patients. Due to the 
heterogeneity of these conclusions, it was not possible to elucidate 
any trends regarding the relationship between age and QoL in 
patients with an ICD or to determine whether this relationship dif-
fered among ICD recipients compared with the general population.
Relationship Between QoL and  
Shocks in iCD Patients
All but two studies investigated whether a correlation exists 
between the perceived QoL of patients with an ICD and deliv-
ered shocks. Four cross-sectional studies and one cohort study 
did not observe any differences in health-related QoL between 
patients with an ICD who had or had not experienced a shock 
(26–29, 31). In the SCD-HeFT trial, Mark et al. (20) also did not 
observe a difference in QoL, with the exception of those patients 
who were shocked within a month of their QoL assessment. This 
finding suggests that the negative influence of ICD shocks on QoL 
decreases with time. Due to the small number of patients whose 
QoL was measured within a month of ICD shock, this finding 
remains to be reproduced.
Two RCTs reported that QoL of ICD patients depended on the 
number of shocks received. Irvine et al. (19) and Passman et al. 
(22) found a reduced mental well-being only for patients who 
experienced five or more shocks.
Three cross-sectional studies (30, 32, 33) revealed a poorer 
psychological well-being for ICD patients following shocks, 
including psychosocial problems, anxiety, and concerns 
regarding complications. Kamphuis et  al. (25) demonstrated 
decreased physical functioning among patients who had received 
a shock. Schron et al. (23) observed lower physical and mental 
scores among the patients of the AVID trial with a history of ICD 
discharge.
DiSCUSSiON
In general, we could not ascertain a uniform trend regarding the 
QoL of patients who received an ICD. The majority of studies 
concluded that there was no difference between the ICD groups 
and the control groups. For the subgroup of patients who 
experience ICD shocks, the data suggest unchanged or poorer 
QoL compared to ICD patients without ICD discharge. A high 
number of shocks and the recency of shocks appear to correlate 
with reduced QoL. However, an underlying causality cannot be 
deduced from this correlation. It is possible that repeated shock 
experiences will influence a patient’s perception of his health in 
a negative way. It is also possible that sicker patients with poorer 
QoL are increasingly affected by shocks.
Due to differences in control groups, study designs, and 
inclusion and exclusion criteria, there was limited comparability 
TABLe 4 | Findings from the included studies with respect to distinct subcategories of QoL.
Subcategory of QoL Mark 
(20)
Noyes 
(21)
Passman 
(22)
irvine 
(19)
Hsu 
(26)
Schron 
(23)
Leosdottir 
(28)
Newall 
(29)
Czosek 
(31)
Duru 
(27)
Redhead 
(30)
Kamphuis 
(25)
Probst 
(32)
Opic 
(33)
Cross 
(24)
Physical health (physical limitations, 
bodily pain, and self-perception of 
general health status)
n.s. n.s. n.s. n.s.
Physical functioning (focus: physical 
limitations)
n.s. n.s. + n.s. n.s. n.s. n.s. n.s. − n.s.
Physical role (focus: problems with 
work or other activities due to physical 
limitations)
+ n.s. n.s. n.s. n.s.
Bodily pain + n.s. n.s. − n.s. n.s.
Sleep efficiency and quality + +
Self-perception of general health + n.s. n.s. n.s. −
Mental health (social and emotional 
functioning, psychological well-
being, vitality)
+ n.s. + n.s. n.s. n.s. n.s. n.s. n.s.
Social functioning (focus: impact of 
physical or emotional problems on social 
activities)
+ n.s. n.s. n.s. n.s. n.s.
Emotional role (focus: limitations at 
work or other activities due to emotional 
problems)
+ n.s. n.s. n.s. n.s. n.s.
Psychological well-being (focus: anxiety, 
depression, mental health)
n.s. n.s. n.s. n.s. n.s. n.s.
Vitality (focus: subjective well-being, e.g., 
energy level, fatigue)
n.s. + n.s. n.s. n.s. n.s. n.s.
Satisfaction with life −
Anxiety n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s.
Depression + n.s. n.s. n.s. n.s. n.s. n.s.
Reassurance by ICD n.s. +
Perception of being informed about ICD n.s. n.s. n.s.
Bodily awareness n.s.
+, better for ICD group; −, worse for ICD group; n.s., not significant; blank fields, not investigated or not reported.
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and heterogeneous methodological quality among the studies 
reviewed. The three studies that were assessed to be of high 
quality and to have a high level of evidence were the SCD-HeFT 
(20), the MADIT II (21), and the DEFINITE (22) studies, which 
included a total of 4,021 patients. These three RCTs found similar 
QoL between ICD patients and controls under medical treat-
ment. Comparable results were also published in further studies, 
but the reader should keep in mind the frequent differences 
especially in the underlying patient structures. For example, 
Probst et al. (32) detected no relevant differences of Qol in ICD 
patients and controls as well, but compared to SCD-HeFT (20), 
MADIT II (21), and DEFINITE (22), this investigation is focused 
on patients suffering from Brugada syndrome. These patients had 
a relevant lower age (50–54 years) compared with the mean age 
of ICD patients in SCD-HeFT, MADIT, and DEFINITE (ranging 
from 59 to 64 years). Additionally, Brugada patients are less suf-
fering from comorbidities and are more frequently professionally 
active (32).
Because several RCTs have demonstrated that ICDs exert 
a survival advantage over medical treatment (2–9), the alloca-
tion of ICD therapy and medical treatment via randomization 
is ethically questionable. Therefore, the RCTs identified by our 
systematic review were conducted over 10 years ago. The more 
current studies included in our review were observational stud-
ies and were characterized by a lower evidence level. Their small 
patient numbers and their single-center and cross-sectional 
designs further diminished the informative value of these studies. 
The longitudinal studies included in our review had short follow-
up (FU) periods. Three of the six longitudinal studies followed 
patients for only 12 months (19, 23, 25). The FU periods of the 
remaining studies lasted as long as 30, 48, or 63 months (20–22). 
Because QoL is particularly influenced by incisive experiences, 
including device implantation, and habituation, a FU period of 
several years may be more appropriate.
Two additional limitations of the studies that assessed the 
relationship between ICD implantation and various outcomes 
are the impossibility of blinding and the definition of a suitable 
control group. Unblinded cardiologists do not ensure the equal 
treatment of patients who are receiving distinct therapies. Hence, 
there exists a high risk of bias. This is particularly important when 
assessing an outcome such as QoL, which is often influenced by 
a patient’s contact with medical staff. The selection of a control 
group for an ICD population often requires relatively large 
compromises. Patients with an implanted pacemaker, for instance, 
often differ in both their demographic and clinical characteristics. 
They are usually older than patients with an ICD and are more 
likely to be women.
As a procedural limitation of the development of our review, 
the screening of titles as an initial selection step must be 
mentioned. This step is more prone to missing relevant articles 
than screening of abstracts. An additional issue is the inclusion 
of newer studies that were published only following the year 
2000. In some cases, there existed a time lag of several years 
between the completion of the study and the publication of the 
results. Hence, there were studies that investigated patients much 
earlier than the publication date (19, 27). Consequently, the 
technology of the implanted devices and the patients’ awareness 
and acceptance of ICD therapy may not have been comparable. 
Finally, our review did not include systematic reviews and 
meta-analyses, which were, however, used later to check the 
thoroughness of our review.
Previous reviews and meta-analyses on QoL in ICD patients 
drew opposing conclusions. McCready et al. (34) concluded that 
ICD implantation was superior to medical therapy with respect 
to QoL, based on eight studies published between 1995 and 2002. 
Groeneveld et al. (16), who included 27 studies published between 
1995 and 2005, came to the same conclusion. Additionally, they 
emphasized that changes in QoL were strongly dependent on 
the comparison groups. Compared with the general public or 
pacemaker patients, ICD recipients had a lower QoL. Unchanged 
or improved QoL was noted for ICD patients based on pre- and 
post-implant comparisons by Shea (15), who reviewed three trials 
conducted in the 1990s. Francis et  al. (35) included 30 studies 
that were published between 1993 and 2004. Five randomized 
trials suggested either an unchanged or an improved QoL among 
the patients who underwent an ICD implantation. The 16 non-
randomized trials under study showed a balanced result. In their 
meta-analysis, Burke et al. (36) concluded either unchanged or 
poorer QoL for patients who received an ICD. They considered 20 
publications, each of which was published before the year 2000, 
using various comparisons, including pre- and post-implantation 
comparisons and comparisons with cardiac patients who did not 
receive therapy and patients who received antiarrhythmic drug 
therapy.
Our systematic review confirmed the trend observed by 
McCready et  al. (34) and Groeneveld et  al. (16), as we deter-
mined an either unchanged or improved QoL for ICD patients 
compared with patients under optimal medical treatment; 
however, either unchanged or poorer QoL was noted among 
ICD patients compared with pacemaker recipients. However, 
due to both the small number of studies and various limitations 
concerning both methodology and implementation, we do not 
view this trend as firm but rather as a finding that remains to 
be reproduced.
The value of pre- and post-implantation QoL comparisons 
appears to be limited. We expect an imminent implantation to 
strongly influence patients’ QoL and their psychological well-
being in particular. QoL may decrease due to worries about the 
surgical operation or increase due to the expected improvement 
of state of health owing to the ICD. Therefore, we focused on the 
comparison between patients who received an ICD and a non-
ICD control group in our systematic review.
The heterogeneous results of the studies available for our 
review did not permit a definitive answer to the question of 
whether health-related QoL differs between patients with an 
ICD and respective controls. One may remain critical of whether 
patients with pacemakers or patients who have received medi-
cal treatment are representative as control patients. Lower QoL 
was apparent among ICD patients who experienced several 
device discharges. Medical staff should be particularly aware 
of psychological and physical effects in these patients. Future 
research on these open QoL questions is difficult because it is 
currently not ethical to randomize patients to ICD or control 
treatment.
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